Research programme: cannabinoid-based therapeutics - Tetra Bio-Pharma/Panag Pharma

Drug Profile

Research programme: cannabinoid-based therapeutics - Tetra Bio-Pharma/Panag Pharma

Alternative Names: PPP 003; PPP 004

Latest Information Update: 30 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Panag Pharma
  • Developer Panag Pharma; Tetra Bio Pharma
  • Class Analgesics; Anti-inflammatories
  • Mechanism of Action Cannabinoid receptor CB2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Neuropathic pain; Ocular inflammation; Ocular pain
  • Research Inflammation

Most Recent Events

  • 13 Jun 2018 Tetra Bio-Pharma intends to commence a phase I clinical trial for eye pain, inflammation and dry eye in the third quarter of 2018
  • 13 Jun 2018 Tetra Bio-Pharma intends to commence a phase I clinical trial for general neuropathic pain in the third quarter of 2018
  • 30 May 2018 Preclinical trials in Neuropathic pain in Canada (Topical) (Tetra Bio-Pharma pipeline May 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top